Lu Qiang, Luo Yan, Yuan Chao-Xin, Zeng Yong, Wu Hong, Lei Zheng, Zhong Yao, Fan Yu-Ting, Wang Hong-Hao, Luo Yang
Department of Sonography, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China.
World J Gastroenterol. 2008 Jul 7;14(25):4005-10. doi: 10.3748/wjg.14.4005.
To assess the clinical value of contrast-enhanced intraoperative ultrasound (CE-IOUS) as a novel tool in partial hepatectomy for cirrhotic patients with hepatocellular carcinoma (HCC).
From January 2007 to September 2007, a total of 20 consecutive cirrhotic patients with HCC scheduled to undergo partial hepatectomy were studied. Preoperative contrast enhanced computer tomography (CT) and/or magnetic resonance (MR) scans were performed within 1-2 wk before operation. Intraoperative ultrasound (IOUS) and CE-IOUS were carried out after mobilization of the liver. Lesions on precontrast and postcontrast scans were counted and mapped. CE-IOUS was performed with intravenous injection of ultrasound contrast agents SonoVue (Bracco Imaging, Milan, Italy). Arterial, portal and late phases of contrast enhancement were recorded and analyzed. Nodules showing arterial phase hyper-enhancing and/or hypo-enhancing in late parenchymal phase were considered malignant and removed surgically. Ultrasound-guided biopsy and ethanol ablation would be an option if the nodule could not be removed surgically. Newly detected nodules on IOUS showing iso-enhancement in both arterial and late phases were considered benign. These nodules were either removed surgically if they were close to the main lesion or followed by examinations of alpha-fetoprotein (AFP) level and ultrasound and/or CT/MR every 3 mo.
IOUS found 41 nodules in total, among which 17 (41.46%) were newly detected compared to preoperative imaging. Thirty-three nodules were diagnosed malignant by CE-IOUS, including one missed by IOUS. The sensitivity and specificity of CE-IOUS on detecting HCC nodules are 100% (33/33 and 100% (9/9), respectively. Nine nodules were considered benign by CE-IOUS, four was confirmed at histology and five by follow-up. CE-IOUS changed the surgical strategy in 35% (7/20) of patients and avoid unnecessary intervention in 30% (6/20) of patients.
CE-IOUS is a useful means to characterize the nodules detected by IOUS in cirrhotic liver, to find isoechoic HCC nodules which can not be shown on IOUS and to improve the accuracy of conventional IOUS, thus it can be used as an essential tool in the surgical treatment of cirrhotic patients with HCC.
评估术中超声造影(CE-IOUS)作为一种新型工具在肝硬化肝细胞癌(HCC)患者肝部分切除术中的临床价值。
2007年1月至2007年9月,对连续20例计划行肝部分切除术的肝硬化HCC患者进行研究。术前1-2周内行增强计算机断层扫描(CT)和/或磁共振成像(MR)扫描。肝脏游离后进行术中超声(IOUS)和CE-IOUS检查。对造影前和造影后的扫描图像上的病灶进行计数和定位。CE-IOUS通过静脉注射超声造影剂声诺维(意大利米兰百胜公司)进行。记录并分析动脉期、门静脉期和延迟期的造影增强情况。动脉期高增强和/或实质期延迟低增强的结节被视为恶性并手术切除。如果结节无法手术切除,超声引导下活检和乙醇消融将作为一种选择。IOUS上新发现的动脉期和延迟期均呈等增强的结节被视为良性。如果这些结节靠近主要病灶则手术切除,否则每3个月检测甲胎蛋白(AFP)水平并进行超声和/或CT/MR检查。
IOUS共发现41个结节,其中与术前影像学检查相比新发现17个(41.46%)。CE-IOUS诊断出33个恶性结节,其中1个为IOUS漏诊。CE-IOUS检测HCC结节的敏感性和特异性分别为100%(33/33)和100%(9/9)。CE-IOUS认为9个结节为良性,4个经组织学证实,5个经随访证实。CE-IOUS改变了35%(7/20)患者的手术策略,避免了30%(6/20)患者的不必要干预。
CE-IOUS是一种有用的手段,可用于鉴别肝硬化肝脏中IOUS检测到的结节,发现IOUS上无法显示的等回声HCC结节,并提高传统IOUS的准确性,因此可作为肝硬化HCC患者手术治疗的重要工具。